- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04224701
A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults
May 6, 2022 updated by: International AIDS Vaccine Initiative
A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted in Healthy, HIV-uninfected Adults
This is a phase 1 clinical trial to evaluate the safety, tolerability, and immunogenicity of HIV-1 envelope protein BG505 SOSIP.GT1.1 gp140 trimer Vaccine, Adjuvanted, in up to 48 healthy HIV-uninfected adult volunteers.
Study Overview
Status
Active, not recruiting
Conditions
Detailed Description
This is a phase 1 clinical trial to evaluate the safety, tolerability, and immunogenicity of HIV-1 envelope protein BG505 SOSIP.GT1.1 gp140 trimer Vaccine, Adjuvanted, in up to 48 healthy HIV-uninfected adult volunteers.
BG505 SOSIP.GT1.1 is a soluable, cleavage-competent, trimeric HIV-1 envelope glycoprotein gp140 formulated in 0.55mL at 2mg/mL in 20 mM Tris, 100 mM naCL, pH 7.5 and will be administered IM.
Study Type
Interventional
Enrollment (Anticipated)
48
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Amsterdam, Netherlands
- The Amsterdam University Medical Centers
-
-
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20052
- George Washington University
-
-
New York
-
New York, New York, United States, 10065
- Rockefeller University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 51 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy adults as assessed by a medical history, physical exam, and laboratory tests;
- At least 18 years of age on the day of screening and has not reached his/her 51 birthday on the day of first IP administration;
- Willing to comply with the requirements of the protocol and be available for follow-up for the planned duration of the study;
- In the opinion of the Principal Investigator or designee and based on Assessment of Informed Consent Understanding results, has understood the information provided and potential impact and/or risks linked to IP administration and participation in the trial; written informed consent will be obtained from the volunteer before any study-related procedures are performed;
- Willing to undergo HIV testing, risk reduction counseling and receive HIV test results;
- All volunteers born female who are engaging in sexual activity that could lead to pregnancy must commit to use an effective method of contraception at the time of the first IP administration and for 4 months following the last IP administration.
- All volunteers born female who are not heterosexually active at screening must agree to utilize an effective method of contraception if they become heterosexually active as outlined above;
- All volunteers born female must be willing to undergo urine pregnancy tests at time points indicated in the Schedule of Procedures
- All sexually active volunteers born male, regardless of reproductive potential, must be willing to use an effective method of contraception (such as consistent condom use) from the day of the first IP administration until at least 4 months after the last IP administration;
- Willing to forgo donations of blood, or any other tissues during the study and, for those who test HIV-positive due to IP-induced antibodies, until the anti-HIV antibody titers become undetectable.
- For sites in the European Union (EU), consent to the collection and use of personal data in compliance with the General Data Protection Regulation (GDPR)
Exclusion Criteria:
- Confirmed HIV-1 or HIV-2 infection;
- Any clinically relevant abnormality on history or examination, including history of immunodeficiency or autoimmune disease; use of systemic corticosteroids (the use of topical or inhaled steroids is permitted), immunosuppressive, anticancer, antituberculosis or other medications considered significant by the investigator within the previous 6 months;
- Any clinically significant acute or chronic medical condition that is considered progressive or in the opinion of the investigator makes the volunteer unsuitable for participation in the study;
Reported behavior which put the volunteer at risk for HIV infection within 6 months prior to IP administration, as defined by:
- Unprotected sexual intercourse with a known HIV-infected person, a partner known to be at high risk for HIV infection or a casual partner (i.e., no continuing established relationship)
- Engaged in sex work
- Frequent excessive daily alcohol use or frequent binge drinking, or any other use of illicit drugs
- History of newly-acquired syphilis, gonorrhea, non-gonococcal urethritis, HSV-2, chlamydia, pelvic inflammatory disease (PID), trichomonas, mucopurulent cervicitis, epididymitis, proctitis, lymphogranuloma venereum, chancroid, or hepatitis B or hepatitis C;
- Three or more sexual partners
- If female, pregnant or planning a pregnancy during the period of enrolment until 4 months after the last IP administration; or lactating;
- Bleeding disorder that was diagnosed by a physician (e.g., factor deficiency, coagulopathy or platelet disorder that requires special precautions)
- Infectious disease diagnosis: chronic hepatitis B infection (HbsAg-positive), current hepatitis C infection (HCV Ab positive and HCV RNA positive or interferon-alfa treatment for hepatitis C infection in the past year or interferon-alfa-free treatment for hepatitis C infection completed in the past 6 months), or active syphilis (screening and confirmatory tests);
- History of splenectomy;
Any of the following abnormal laboratory parameters listed below:
Hematology
- Hemoglobin - <10.5 g/dl or <6.5 mmol/L in females; <11.0 g/dl or <6.8 mmol/L in males
- Absolute Neutrophil Count (ANC) - ≤1,000/mm3 or < 1.0 x 109 cells/L
- Absolute Lymphocyte Count (ALC) - ≤650/mm3 or < 0.65 x 109 cells/L
- Platelets - <125,000 cells/mm3 or < 125 x 109 cells/L
Chemistry
- Creatinine - >1.1 x upper limit of normal (ULN)
- AST - >1.25 x ULN
- ALT - >1.25 x ULN
Urinalysis
Clinically significant abnormal dipstick confirmed by microscopy:
- Protein = 1+ or more
- Blood = 2+ or more (not due to menses)
- Receipt of live attenuated vaccine within the previous 30 days or planned receipt within 30 days after IP administration; or receipt of other vaccine within the previous 14 days or planned receipt within 14 days after IP administration. (Exception is live attenuated influenza vaccine within 14 days.);
- Receipt of blood transfusion or blood-derived products within the previous 3 months;
- Participation in another clinical trial of an investigational product currently, within the previous 3 months or expected participation during this study; concurrent participation in an observational trial not requiring blood or tissue sample collection is not an exclusion;
- Prior receipt of any investigational HIV vaccine candidate or HIV monoclonal antibody Note: receipt of placebo in a previous HIV vaccine trial or monoclonal antibody trial will not exclude a volunteer from participation if documentation is available and the Medical Monitor gives approval;
- History of significant local or systemic reactogenicity to vaccines (e.g., anaphylaxis, respiratory difficulties, angioedema, injection site necrosis or ulceration);
- Psychiatric condition that compromises safety of the volunteer and precludes compliance with the protocol. Specifically excluded are persons with psychoses within the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years;
- Seizure disorder: A volunteer who has had a seizure in the last 3 years is excluded. (Not excluded: a volunteer with a history of seizures who has neither required medications nor had a seizure for 3 years);
- History of malignancy in the past 5 years (prior to screening) or ongoing malignancy (a history of completely excised malignancy that is considered cured is not an exclusion);
- Active, serious infections requiring antibiotic, antiviral or antifungal therapy within 30 days prior to enrolment;
- Body mass index (BMI) ≥35;
- Body weight <110 pounds (50 kg);
- Prior daily use of NSAID/aspirin that cannot be held for 5 days prior to the leukapheresis procedure (if required by the study site);
- If, in the opinion of the Principal Investigator, it is not in the best interest of the volunteer to participate in the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Investigational Product, 30 µg/ Placebo
30 µg IM, months 0, 2 and 6
|
30 µg
300 µg
Tris NaCl Diluent
|
Experimental: Investigational Product, 300 µg/ Placebo
300 µg IM, months 0, 2 and 6
|
30 µg
300 µg
Tris NaCl Diluent
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety - reactogenicity
Time Frame: 7 Days
|
Proportion of volunteers with Grade 2 or greater reactogenicity (i.e., solicited adverse events) from Day 0 through Day 7 after each investigational product (IP) administration
|
7 Days
|
Safety - IP related unsolicited adverse events
Time Frame: 28 days
|
Proportion of volunteers with IP-related unsolicited adverse events (AEs), including safety laboratory (biochemical, hematological) parameters, from the day of each IP administration up to 28 days post each IP administration
|
28 days
|
Safety - Grade 2 or greater unsolicited AEs
Time Frame: 28 days
|
Proportion of volunteers with Grade 2 or greater unsolicited adverse events (AEs), including safety laboratory (biochemical, hematological) parameters, from the day of each IP administration up to 28 days post each IP administration
|
28 days
|
Safety - IP related SAEs
Time Frame: 18 Months
|
Proportion of volunteers with IP-related serious adverse events (SAEs) throughout the study period
|
18 Months
|
Safety - pIMDs
Time Frame: 18 Months
|
Proportion of volunteers in each group with potential immune-mediated diseases (pIMDs) from the day of first IP administration throughout the study period
|
18 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Immunogenicity - Frequency Ab responses
Time Frame: 6 Months
|
Frequency of binding antibody responses to GT1.1 trimer after the first, second, and/or third IP administrations compared to baseline
|
6 Months
|
Immunogenicity - Magnitude Ab responses
Time Frame: 6 Months
|
Magnitude of binding antibody responses to GT1.1 trimer after the first, second, and/or third IP administrations compared to baseline
|
6 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Godelieve de Bree, MD, PhD, Amsterdam Umc, Location Vumc
- Principal Investigator: David Joseph Diemert, MD, George Washington University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2020
Primary Completion (Anticipated)
August 1, 2023
Study Completion (Anticipated)
December 1, 2023
Study Registration Dates
First Submitted
December 19, 2019
First Submitted That Met QC Criteria
January 8, 2020
First Posted (Actual)
January 13, 2020
Study Record Updates
Last Update Posted (Actual)
May 10, 2022
Last Update Submitted That Met QC Criteria
May 6, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
- IAVI C101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted
-
International AIDS Vaccine InitiativeMassachusetts General Hospital; GlaxoSmithKline; Fred Hutchinson Cancer Research... and other collaboratorsCompleted
-
International AIDS Vaccine InitiativeNational Institute of Allergy and Infectious Diseases (NIAID); Access to Advanced...Not yet recruiting
-
International AIDS Vaccine Initiative3M; Polymun Scientific GmbH; Access to Advanced Health Institute (AAHI)Not yet recruiting
-
National Institute of Allergy and Infectious Diseases...Fred Hutchinson Cancer Center; International AIDS Vaccine Initiative; HIV Vaccine... and other collaboratorsActive, not recruiting